Artiva Biotherapeutics, Inc.(ARTV)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ARTV Artiva Biotherapeutics, Inc.

盘前交易 10-01 05:18:05 EDT

7.12

+0.09

+1.28%

盘前6.96

-0.16-2.24%

05:11 EDT

最高7.40	最低6.96	成交量38.40万
今开7.10	昨收7.03	日振幅6.26%
总市值3.48亿	流通市值1.35亿	总股本4,889万
成交额274.67万	换手率2.02%	流通股本1,898万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ARTV","market":"US","secType":"STK","nameCN":"Artiva Biotherapeutics, Inc.","latestPrice":7.12,"timestamp":1790798400000,"preClose":7.03,"halted":0,"volume":383976,"hourTrading":{"tag":"盘前","latestPrice":6.9604,"preClose":7.12,"latestTime":"05:11 EDT","volume":945,"amount":6738.879105,"timestamp":1790845873419,"change":-0.1596,"changeRate":-0.022416,"amplitude":0.037781},"delay":0,"changeRate":0.012802275960170676,"floatShares":18984416,"shares":48885777,"eps":-3.20842,"marketStatus":"盘前交易","change":0.09,"latestTime":"10-01 05:18:05 EDT","open":7.1,"high":7.4,"low":6.96,"amount":2746707.04008,"amplitude":0.062589,"askPrice":7.86,"askSize":100,"bidPrice":6.89,"bidSize":132,"shortable":3,"etf":0,"ttmEps":-3.20842,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790861400000},"marketStatusCode":1,"adr":0,"listingDate":1721361600000,"exchange":"NASDAQ","adjPreClose":7.12,"preHourTrading":{"tag":"盘前","latestPrice":6.9604,"preClose":7.12,"latestTime":"05:11 EDT","volume":945,"amount":6738.879105,"timestamp":1790845873419,"change":-0.1596,"changeRate":-0.022416,"amplitude":0.037781},"postHourTrading":{"tag":"盘后","latestPrice":7.3482,"preClose":7.12,"latestTime":"19:30 EDT","volume":9541,"amount":68208.3796,"timestamp":1790811003547,"change":0.2282,"changeRate":0.032051,"amplitude":0.035843},"volumeRatio":0.8294113835545701,"impliedVol":2.2011,"impliedVolPercentile":0.96},"requestUrl":"/m/hq/s/ARTV","defaultTab":"news","newsList":[{"id":"1193292405","title":"Artiva Biotherapeutics公布2026年剩余时间Allonk®数据披露计划及研发里程碑最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1193292405","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193292405?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:31","pubTimestamp":1788867072,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics, Inc.今日宣布，公司已就计划中的Allonk®数据披露及2026年剩余时间内的关键研发里程碑作出最新更新。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107426732","title":"Artiva Biotherapeutics完成3亿美元普通股及预先注资认股权证承销发行定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1107426732","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107426732?lang=zh_cn&edition=full","pubTime":"2026-05-08 18:56","pubTimestamp":1778237809,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics, Inc. (简称Artiva) 已正式确定其总额达3亿美元的承销发行定价方案。此次发行包含普通股及预先注资认股权证的组合配售，标志着该公司资本运作的重要进展。通过此类融资手段，Artiva有望进一步强化其细胞治疗平台的研发投入与临床推进能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117389399","title":"Artiva Biotherapeutics公司定价发行2390万股普通股 每股11.52美元及220万份预融资权证 每股11.5199美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1117389399","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117389399?lang=zh_cn&edition=full","pubTime":"2026-05-08 18:54","pubTimestamp":1778237655,"startTime":"0","endTime":"0","summary":"生物技术企业Artiva Biotherapeutics Inc（股票代码：ARTV）正式公布其新股发行定价方案。根据公告，公司将以每股11.52美元的价格公开发行2390万股普通股，同时以每股11.5199美元的定价配售220万份预融资权证。此次融资将为企业后续研发管线推进提供资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180304875","title":"Artiva Biotherapeutics暂停与Leerink Partners达成的普通股销售协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1180304875","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180304875?lang=zh_cn&edition=full","pubTime":"2026-05-08 18:42","pubTimestamp":1778236942,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics公司已根据提交给美国证券交易委员会的文件，暂停了其依据与Leerink Partners签订的销售协议进行的普通股发行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145868841","title":"Artiva Biotherapeutics公司现金储备达8680万美元 资金可支撑运营至2027年第二季度","url":"https://stock-news.laohu8.com/highlight/detail?id=1145868841","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145868841?lang=zh_cn&edition=full","pubTime":"2026-05-08 18:35","pubTimestamp":1778236501,"startTime":"0","endTime":"0","summary":"截至2026年3月31日，Artiva Biotherapeutics公司持有的现金、现金等价物及投资总额达到8680万美元。这一充足的资金储备将确保公司运营持续至2027年第二季度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139365930","title":"Artiva公布Allonk®治疗多种自身免疫疾病的积极初期临床数据，并与FDA达成共识拟于2026年启动类风湿关节炎三期注册试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1139365930","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139365930?lang=zh_cn&edition=full","pubTime":"2026-05-08 18:31","pubTimestamp":1778236316,"startTime":"0","endTime":"0","summary":"生物技术公司Artiva Biotherapeutics宣布，其核心产品Allonk®在针对多种自身免疫性疾病的早期临床研究中取得突破性进展。数据显示该疗法在安全性及有效性方面均表现出积极信号。与此同时，公司已与美国食品药品监督管理局（FDA）就开展类风湿关节炎的三期注册临床试验达成关键共识，预计将于2026年正式启动这项关键性研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123757407","title":"Artiva Biotherapeutics公司早期数据：难治性类风湿关节炎患者六个月时ACR50应答率达71%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123757407","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123757407?lang=zh_cn&edition=full","pubTime":"2026-05-08 18:31","pubTimestamp":1778236279,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics公司公布的最新初步研究数据显示，在针对难治性类风湿关节炎患者的临床试验中，接受治疗六个月后达到ACR50应答标准的患者比例高达71%。这一积极数据展现了该公司在细胞疗法领域的研发潜力。\nACR50是评估类风湿关节炎治疗效果的权威指标，代表患者症状和身体功能至少改善50%。对于现有疗法反应不佳的难治性患者群体而言，达到如此高比例的应答率具有重要临床意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136199055","title":"Artiva Biotherapeutics公司Allonk疗法展现良好耐受性，未现CRS、ICANS或停药案例","url":"https://stock-news.laohu8.com/highlight/detail?id=1136199055","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136199055?lang=zh_cn&edition=full","pubTime":"2026-05-08 18:31","pubTimestamp":1778236278,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics公司（股票代码：ARTV）近日公布其候选疗法Allonk的最新研究数据。该疗法在临床试验中表现出优异的耐受性特征，全程未观察到细胞因子释放综合征（CRS）、免疫效应细胞相关神经毒性综合征（ICANS）等不良反应，亦无受试者因不良事件中止治疗。\n这一积极结果标志着Allonk在安全性方面取得重要突破，为后续临床开发奠定坚实基础。研究数据进一步验证了该疗法潜在的治疗窗口与可控的安全性轮廓，展现出良好的临床应用前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199193235","title":"Artiva Biotherapeutics Inc预计于2026年下半年启动注册性试验，关键数据将于2028年下半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1199193235","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199193235?lang=zh_cn&edition=full","pubTime":"2026-05-08 18:31","pubTimestamp":1778236274,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics Inc宣布，其关键注册性临床试验预计将于2026年下半年正式启动，而试验的主要数据结果计划在2028年下半年对外公布。这一时间表的公布为投资者提供了公司研发管线推进的明确路线图。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518273406","title":"Artiva Biotherapeutics, Inc.盘中异动 大幅下挫5.78%报5.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518273406","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518273406?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:32","pubTimestamp":1741617139,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时32分，Artiva Biotherapeutics, Inc.股票出现波动，股价急速下跌5.78%。Artiva Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.06%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Aeon Biopharma, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Aeon Biopharma, Inc.较为活跃，换手率分别为3461.22%、735.14%、528.62%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.，振幅分别为41.36%、40.33%、40.24%。Artiva Biotherapeutics, Inc.公司简介：Artiva Biotherapeutics Inc 是一家生物制药公司。该公司的管道项目包括Artiva-Funded Trials和Collaborator-Funded Trials。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223219abf31348&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223219abf31348&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517016480","title":"Artiva Biotherapeutics, Inc.盘中异动 股价大涨5.12%报4.72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517016480","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517016480?lang=zh_cn&edition=full","pubTime":"2025-03-06 23:24","pubTimestamp":1741274664,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日23时24分，Artiva Biotherapeutics, Inc.股票出现波动，股价快速拉升5.12%。Artiva Biotherapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.55%。其相关个股中，Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Aeon Biopharma, Inc.、Plus Therapeutics, Inc.涨幅较大，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Aditxt, Inc.较为活跃，换手率分别为1547.16%、1402.06%、80.11%，振幅较大的相关个股有Aeon Biopharma, Inc.、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Moolec Science Sa C/Wts ，振幅分别为65.26%、44.64%、44.44%。Artiva Biotherapeutics, Inc.公司简介：Artiva Biotherapeutics Inc 是一家生物制药公司。该公司的管道项目包括Artiva-Funded Trials和Collaborator-Funded Trials。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306232424a2629e3a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306232424a2629e3a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517438449","title":"Artiva Biotherapeutics, Inc.盘中异动 快速下挫5.01%报4.17美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517438449","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517438449?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:54","pubTimestamp":1741186470,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时54分，Artiva Biotherapeutics, Inc.股票出现波动，股价大幅下跌5.01%。Artiva Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.51%。其相关个股中，Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Silexion Therapeutics Corp涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为667.04%、273.50%、230.98%，振幅较大的相关个股有Nkgen Biotech, Inc.、180 Life Sciences Corp C/Wts 07/11/2025、Silexion Therapeutics Corp，振幅分别为40.77%、36.89%、33.33%。Artiva Biotherapeutics, Inc.公司简介：Artiva Biotherapeutics Inc 是一家生物制药公司。该公司的管道项目包括Artiva-Funded Trials和Collaborator-Funded Trials。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305225430963ae24b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305225430963ae24b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ARTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516187668","title":"Artiva Biotherapeutics, Inc.盘中异动 快速下挫5.54%报3.92美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516187668","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516187668?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:21","pubTimestamp":1741033294,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时21分，Artiva Biotherapeutics, Inc.股票出现异动，股价快速下跌5.54%。Artiva Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.07%。其相关个股中，Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Celularity Inc C/Wts 16/07/2026 涨幅较大，Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4602.99%、213.18%、183.34%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Artiva Biotherapeutics, Inc.公司简介：Artiva Biotherapeutics Inc 是一家生物制药公司。该公司的管道项目包括Artiva-Funded Trials和Collaborator-Funded Trials。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503040421349637fa5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503040421349637fa5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ARTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516437493","title":"Artiva Biotherapeutics, Inc.盘中异动 股价大涨5.09%报3.92美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516437493","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516437493?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:54","pubTimestamp":1740761671,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日00时54分，Artiva Biotherapeutics, Inc.股票出现波动，股价快速拉升5.09%。Artiva Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.45%。其相关个股中，Bioxcel Therapeutics, Inc.、Revolution Medicines Inc C/Wts 17/12/2026 、Exicure, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Enveric Biosciences, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为3021.47%、494.75%、369.99%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 ，振幅分别为57.80%、48.19%、46.60%。Artiva Biotherapeutics, Inc.公司简介：Artiva Biotherapeutics Inc 是一家生物制药公司。该公司的管道项目包括Artiva-Funded Trials和Collaborator-Funded Trials。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030100543198969a29&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030100543198969a29&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ARTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514851228","title":"Artiva Biotherapeutics, Inc.盘中异动 大幅拉升5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514851228","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514851228?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:07","pubTimestamp":1740582449,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时07分，Artiva Biotherapeutics, Inc.股票出现波动，股价快速拉升5.32%。Artiva Biotherapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.07%。其相关个股中，Enveric Biosciences, Inc.、Renovaro Inc.、Humacyte Inc C/Wts 27/08/2026 涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为4735.86%、163.29%、151.11%，振幅较大的相关个股有Enveric Biosciences, Inc.、Humacyte Inc C/Wts 27/08/2026 、Renovaro Inc.，振幅分别为161.02%、39.47%、29.31%。Artiva Biotherapeutics, Inc.公司简介：Artiva Biotherapeutics Inc 是一家生物制药公司。该公司的管道项目包括Artiva-Funded Trials和Collaborator-Funded Trials。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262307299893b1e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262307299893b1e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ARTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513296857","title":"Artiva Biotherapeutics, Inc.盘中异动 早盘急速拉升5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513296857","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513296857?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:36","pubTimestamp":1740148571,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时36分，Artiva Biotherapeutics, Inc.股票出现波动，股价大幅上涨5.15%。Artiva Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.26%。其相关个股中，Osr Holdings, Inc.、Osr Holdings Inc C/Wts 09/02/2028 、Omega Therapeutics, Inc.涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为72.82%、65.66%、17.29%，振幅较大的相关个股有Lexaria Bioscience Corp C/Wts 14/01/2026 、Osr Holdings Inc C/Wts 09/02/2028 、Osr Holdings, Inc.，振幅分别为33.83%、30.00%、25.39%。Artiva Biotherapeutics, Inc.公司简介：Artiva Biotherapeutics Inc 是一家生物制药公司。该公司的管道项目包括Artiva-Funded Trials和Collaborator-Funded Trials。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223612abd7b0b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223612abd7b0b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512161194","title":"Artiva Biotherapeutics, Inc.盘中异动 早盘大幅下挫6.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512161194","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512161194?lang=zh_cn&edition=full","pubTime":"2025-02-18 23:29","pubTimestamp":1739892553,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日23时29分，Artiva Biotherapeutics, Inc.股票出现波动，股价大幅跳水6.31%。Artiva Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.66%。其相关个股中，Estrella Immunopharma Inc C/Wts 29/09/2028、Allogene Therapeutics, Inc.、Solid Biosciences Inc.涨幅较大，Aditxt, Inc.、Moleculin Biotech, Inc.、Solid Biosciences Inc.较为活跃，换手率分别为363.49%、157.25%、137.43%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Allogene Therapeutics, Inc.、Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 ，振幅分别为148.75%、79.17%、51.40%。Artiva Biotherapeutics, Inc.公司简介：Artiva Biotherapeutics Inc 是一家生物制药公司。该公司的管道项目包括Artiva-Funded Trials和Collaborator-Funded Trials。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218232913a24ab9dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218232913a24ab9dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ARTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511778395","title":"Artiva Biotherapeutics, Inc.盘中异动 临近收盘股价大涨5.43%报3.88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511778395","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511778395?lang=zh_cn&edition=full","pubTime":"2025-02-14 04:56","pubTimestamp":1739480206,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日04时56分，Artiva Biotherapeutics, Inc.股票出现异动，股价大幅上涨5.43%。Artiva Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.16%。其相关个股中，Moleculin Biotech, Inc.、Dominari Holdings Inc.、Edesa Biotech, Inc.涨幅较大，Edesa Biotech, Inc.、Moleculin Biotech, Inc.、Tc Biopharm  Plc较为活跃，换手率分别为3296.69%、2344.61%、1272.12%，振幅较大的相关个股有Moleculin Biotech, Inc.、Edesa Biotech, Inc.、Immatics N V C/Wts 01/07/2025 ，振幅分别为733.31%、95.15%、92.30%。Artiva Biotherapeutics, Inc.公司简介：Artiva Biotherapeutics Inc 是一家生物制药公司。该公司的管道项目包括Artiva-Funded Trials和Collaborator-Funded Trials。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214045646962205e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214045646962205e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ARTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510332592","title":"Artiva Biotherapeutics, Inc.盘中异动 大幅跳水5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510332592","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510332592?lang=zh_cn&edition=full","pubTime":"2025-02-12 00:54","pubTimestamp":1739292856,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日00时54分，Artiva Biotherapeutics, Inc.股票出现波动，股价大幅下挫5.11%。Artiva Biotherapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.46%。其相关个股中，Omega Therapeutics, Inc.、Lipella Pharmaceuticals Inc.、Oramed Pharmaceuticals Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为2993.01%、1329.94%、437.01%，振幅较大的相关个股有Omega Therapeutics, Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.，振幅分别为143.33%、59.46%、58.60%。Artiva Biotherapeutics, Inc.公司简介：Artiva Biotherapeutics Inc 是一家生物制药公司。该公司的管道项目包括Artiva-Funded Trials和Collaborator-Funded Trials。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212005416a24219a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212005416a24219a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510663948","title":"Artiva Biotherapeutics, Inc.盘中异动 大幅上涨5.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510663948","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510663948?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:55","pubTimestamp":1739199300,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时55分，Artiva Biotherapeutics, Inc.股票出现波动，股价大幅拉升5.88%。Artiva Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.19%。其相关个股中，Biodexa Pharmaceuticals Plc、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Neurosense Therapeutics Ltd C/Wts 10/11/2026 涨幅较大，Biodexa Pharmaceuticals Plc、Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.较为活跃，换手率分别为2217.76%、1397.00%、802.72%，振幅较大的相关个股有Biodexa Pharmaceuticals Plc、Ocean Biomedical, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为59.71%、48.38%、39.13%。Artiva Biotherapeutics, Inc.公司简介：Artiva Biotherapeutics Inc 是一家生物制药公司。该公司的管道项目包括Artiva-Funded Trials和Collaborator-Funded Trials。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021022550198807d20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021022550198807d20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ARTV"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.artivabio.com","stockEarnings":[{"period":"1week","weight":-0.0777},{"period":"1month","weight":-0.3699},{"period":"3month","weight":-0.2591},{"period":"6month","weight":0.0564},{"period":"1year","weight":1.4808},{"period":"ytd","weight":0.6597}],"compareEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":-0.0058},{"period":"3month","weight":0.024},{"period":"6month","weight":0.1628},{"period":"1year","weight":0.1448},{"period":"ytd","weight":0.1184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Artiva Biotherapeutics, Inc.于2019年2月14日在特拉华州注册成立。该公司是一家临床阶段的生物技术公司，专注于为患有破坏性自身免疫性疾病和癌症的患者开发基于自然杀伤（NK）细胞的疗法。","exchange":"NASDAQ","name":"Artiva Biotherapeutics, Inc.","nameEN":"Artiva Biotherapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Artiva Biotherapeutics, Inc.(ARTV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Artiva Biotherapeutics, Inc.(ARTV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Artiva Biotherapeutics, Inc.,ARTV,Artiva Biotherapeutics, Inc.股票,Artiva Biotherapeutics, Inc.股票老虎,Artiva Biotherapeutics, Inc.股票老虎国际,Artiva Biotherapeutics, Inc.行情,Artiva Biotherapeutics, Inc.股票行情,Artiva Biotherapeutics, Inc.股价,Artiva Biotherapeutics, Inc.股市,Artiva Biotherapeutics, Inc.股票价格,Artiva Biotherapeutics, Inc.股票交易,Artiva Biotherapeutics, Inc.股票购买,Artiva Biotherapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Artiva Biotherapeutics, Inc.(ARTV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Artiva Biotherapeutics, Inc.(ARTV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}